U.S. Markets closed

Intercept to Present at Upcoming Investor Conferences in May

NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conferences:

  • Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV at 11:20 a.m. PT on Tuesday, May 14, 2019
  • UBS Global Healthcare Conference in New York, NY at 1:00 p.m. ET on Tuesday, May 21, 2019
  • RBC Capital Markets Global Healthcare Conference in New York, NY at 11:30 a.m. ET on Wednesday, May 22, 2019

Webcast information for these events will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

CONTACT

For more information about Intercept, please contact:

Justine O’Malley
+1-646-931-1180
investors@interceptpharma.com

Media inquiries: media@interceptpharma.com